Back to Journals » Patient Preference and Adherence » Volume 2

Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program

Authors Abughosh S, Kogut S

Published 20 March 2008 Volume 2008:2 Pages 79—85


Susan M Abughosh1, Stephen J Kogut2

1Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences (MCPHS), MA, USA; 2Department of Pharmacy Practice, Program in Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island (URI), College of Pharmacy, RI, USA

Objective: To compare levels of persistency between cholinesterase inhibitors (ChEIs) among a Medicaid patient population of older adults.

Methods: Survival analysis was used to assess differences in discontinuation between ChEIs (donepezil versus rivastigmine and galantamine), and for difference in patient gender, age, race, and care setting.

Results: Rates of discontinuation increased from 42.7% (95% CI = 39.9–45.5) at 12 months to 84.8% (95% CI = 82.3–87.3) at 24 months. In multivariate models, no significant difference in discontinuation existed prior to 365 days. However, patients dispensed donepezil were less likely to discontinue as compared with users of the other two ChEIs after the first year (RR = 0.70; CI = 0.499–0.983; p < 0.04). Patients of white race were less likely to discontinue (RR = 0.549; 95% CI = 0.43–0.82; p = 0.0015), while gender, care setting, and age were not associated with discontinuation.

Conclusions: One-year persistence rates were similar between different ChEIs. Among patients persisting with ChEI medication for at least 12 months, users of donepezil were slightly more likely to continue to persist at 24 months. Nearly half of patients failed to persist with ChEI therapy for at least 12 months. Our findings underscore the limitations of the ChEI medications and the urgent need for effective and tolerable therapeutic options for patients having dementia.

Keywords: persistence, elderly, alzheimer’s disease, cholinesterase inhibitors, medicaid

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M

OncoTargets and Therapy 2015, 8:1149-1156

Published Date: 22 May 2015

Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads

Schroyen S, Adam S, Jerusalem G, Missotten P

Clinical Interventions in Aging 2015, 10:117-125

Published Date: 31 December 2014

Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

Benekli M, Yalcin S, Ozkan M, Elkiran ET, Sevinc A, Cabuk D, Coskun HS, Oksuzoglu B, Bayar B, Akbulat A, Ozet A

OncoTargets and Therapy 2015, 8:1-5

Published Date: 15 December 2014

Multidisciplinary care in pediatric oncology

Cantrell MA, Ruble K

Journal of Multidisciplinary Healthcare 2011, 4:171-181

Published Date: 30 May 2011

Use of electronic medical records in oncology outcomes research

Gena Kanas, Libby Morimoto, Fionna Mowat, et al

ClinicoEconomics and Outcomes Research 2010, 2:1-14

Published Date: 24 February 2010